Vivos Therapeutics, Inc. VVOS

Company Overview

Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a U.S.-based medical technology and healthcare services company focused on the diagnosis, treatment, and management of sleep-disordered breathing conditions, including mild-to-moderate obstructive sleep apnea (OSA) and snoring. The company operates primarily within the dental sleep medicine and airway-focused healthcare markets, offering proprietary oral appliance therapies and related clinical training programs for dentists and healthcare providers. Its core commercial offerings include the Vivos Method, a treatment protocol designed to address craniofacial and airway-related conditions using customized oral appliances and multidisciplinary care approaches.

The company generates revenue through appliance sales, clinical education and training, licensing programs, and practice support services provided to dental professionals. Vivos positions itself as an alternative or complementary approach to traditional continuous positive airway pressure (CPAP) therapy, emphasizing non-invasive and patient-centered treatment pathways. Founded in 2016 and headquartered in Littleton, Colorado, the company evolved through acquisitions and development of airway-focused treatment technologies, expanding from a provider education platform into a broader sleep-health and therapeutic solutions business.

Business Operations

Vivos operates through integrated healthcare and technology-focused activities centered on dental sleep medicine. Its primary operating activities include sales of proprietary oral medical devices, professional training programs, practice management support, and patient diagnostic services. The company’s appliance portfolio includes products marketed under brands such as DNA, mRNA, and other airway remodeling devices intended for use by trained dental professionals. Revenue is derived from product sales to affiliated providers, educational seminars, certification programs, and ongoing support services for dental practices implementing the Vivos treatment methodology.

The company maintains operations primarily in the United States, while also pursuing broader distribution and clinical relationships internationally through provider networks and strategic collaborations. Vivos has developed partnerships with sleep physicians, dental practices, and healthcare organizations to integrate airway-focused care into broader sleep-health treatment ecosystems. The company also controls intellectual property related to oral appliance therapy protocols and airway treatment methodologies. Public filings and corporate disclosures indicate continuing efforts to expand payer relationships and increase insurance reimbursement accessibility for its therapies.

Strategic Position & Investments

Vivos has pursued a growth strategy centered on expanding awareness and adoption of non-CPAP sleep apnea treatments through provider network expansion, technology integration, and strategic acquisitions. The company has invested in diagnostic and telehealth capabilities intended to support end-to-end patient management, including home sleep testing and data-driven treatment coordination. Its strategy emphasizes scaling provider education programs and increasing the number of dentists certified to deliver Vivos therapies.

The company has also completed acquisitions and investments intended to broaden its clinical capabilities and patient reach. Notable transactions have included acquisitions involving sleep diagnostic and healthcare service assets designed to strengthen vertical integration within the sleep-health ecosystem. Vivos has continued to position itself within emerging healthcare trends emphasizing personalized medicine, minimally invasive therapies, and interdisciplinary treatment approaches. While management has publicly discussed opportunities related to broader sleep-health markets and insurance adoption, some long-term commercialization expectations remain subject to evolving market acceptance and reimbursement dynamics.

Geographic Footprint

Vivos Therapeutics is headquartered in Littleton, Colorado, and conducts most of its commercial operations across the United States through affiliated dental and healthcare provider networks. The company’s provider-focused model allows it to distribute products and services across multiple states without maintaining large-scale traditional clinical infrastructure. Its training and education programs are designed to support nationwide adoption among dental practitioners and sleep-health professionals.

In addition to its domestic presence, Vivos has pursued selective international expansion opportunities through partnerships and provider engagement initiatives in regions outside the United States. Public disclosures indicate interest in extending awareness of airway-focused therapies into broader global markets, though the company’s operational concentration remains primarily North American. Data regarding material international revenue contributions is limited in publicly available filings, and detailed regional financial breakdowns are inconclusive based on available public sources.

Leadership & Governance

Vivos Therapeutics is led by executives with backgrounds in healthcare services, medical technology, dental sleep medicine, and corporate operations. The company’s leadership has emphasized increasing awareness of sleep-disordered breathing, expanding provider adoption, and building integrated treatment pathways that combine diagnostics, therapy, and practice support. Governance and strategic oversight are directed through executive leadership and the company’s board structure as disclosed in public filings, including SEC filings and annual reports.

Key executives include:

• Kirk Huntsman – Chairman and Chief Executive Officer
• Bradley T. Clawson – Chief Financial Officer
• Jeremy A. Manuele – President
• Rama Krishna – Chief Technology Officer

The company’s leadership philosophy has consistently focused on scaling airway-centered healthcare delivery through provider education, proprietary treatment protocols, and expanded clinical integration within the sleep-health market.